Pricing

The U.S. Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) are commitment to support value-based purchasing (VBP) of prescription drugs in Medicaid, despite headlines of CMS’s rejection of a Massachusetts request to make changes in its Medicaid prescription drug benefit.

Charting the course that has led to payer vertical integration and what it may mean for pharma manufacturers.

Practitioners in the field of HEOR training and education outline how the best courses are responding to advancing industry needs.

Executives from diagnostics, payer, pharma, and patient care companies converge to share the inside scoop on outcomes-based contracting.

The biopharma industry should embrace the developments about value assessment in the US and take a leading role in defining and demonstrating what can be considered credible and relevant cost-effectiveness studies, write Ross Maclean and Jeroen Jansen.

Amid contrasting views on the success of the now well-established system of outcomes-based agreements in Italy, further demands on global healthcare budgets will likely point to their adoption on a wider scale

Outcomes-based contracting could be a potential game changer in linking drug cost with value, boosting healthcare efficiency, and ensuring that appropriate patients benefit from innovative medicines. But several complex challenges remain in the bid to make this model a mainstay.

Tackling some of the unintended consequences associated with value-based contracting in pharma and efforts to advance toward sustainable outcomes-based engagement.

Drawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.

If HEOR teams don’t clearly and concisely define themselves, their discipline, and their mission, they risk failure and irrelevance. A thoughtful communications program aimed at colleagues will win them due recognition of the value they bring, a say in key business decisions, and ongoing relevance.

Everyone’s talking value, but not everyone is willing to pin down the elusive concept. Pharm Exec talks with Steven Pearson, founder of the Institute for Clinical Effectiveness Review (ICER), about all things value-based.

The significance of real-world data has been not utilized to the full potential, writes Uttam Barick.

To gain better alignment of coverage and risk, evidence-based arguments are critical during the underwriting process.

A panel of biopharma executives discuss market access and the changing dynamics in reaching physicians and healthcare professionals.

How companies are closing the innovation gap between the lab and the patient, while also creating value for all stakeholders.

Connected ecosystems will change the future of healthcare. Three key value drivers are outlined.

Pharm Exec sits down with AmerisourceBergen supply chain leader Peyton Howell to discuss the latest trends in pharmaceutical distribution, including company efforts to boost efficiency, reliability, and enhance its groundbreaking partnership with Walgreens Boots Alliance.

Jill Wechsler on the need for more efficient methods of documenting treatment benefits in medical practice.

How companies can better integrate valuable data across business functions to meet rising value-chain demands.

There’s a stampede to relate prices to broader health benefits, but little consensus on how to do so, writes Jill Wechsler.

Even though pharma's “dark days” are fading away, the chill of the last few months will not soon be forgotten, writes Tom Norton.

The importance of betting on outcomes, not simply risk sharing, when implementing pharma-payer arrangements. .